CompletedNot Applicable

Evaluation of Pathogenesis and Diagnosis of Mycoplasma Pneumoniae Community-acquired Pneumonia (CAP)

490 participantsStarted 2016-05-01

Plain-language summary

To investigate the Mycoplasma pneumoniae-specific circulating antibody-secreting cell (ASC) response and Mycoplasma pneumoniae-specific interferon (INF)-γ-secreting T cell response, along with polymerase chain reaction (PCR) and serology, in a cohort of children with community-acquired pneumonia (CAP) and controls.

Who can participate

Age range3 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: CAP cohort: * Children of age 3 to 18 years; * In- and outpatients; * Clinically diagnosed community-acquired pneumonia (CAP); Healthy control cohort: \- Healthy asymptomatic children of age 3 to 18 years undergoing an elective surgical procedure; Family control cohort: \- Family members of index CAP patients. Exclusion Criteria: * Hospital-acquired pneumonia; * Immunodeficiencies; * Chronic lung disorders.

What they're measuring

Change in numbers of M. pneumoniae-specific ASCs and M. pneumoniae-specific INF-γ-secreting T cells in blood from inclusion (day 0) to 1-month follow-up (day 28)

Timeframe: At day 0 (inclusion, disease presentation) and at day 28 (follow-up, disease resolution)

Trial details

NCT IDNCT03613636

SponsorUniversity Children's Hospital, Zurich

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-10-31

View on ClinicalTrials.gov More Childhood Pneumonia trials